06:03 EDT Esperion (ESPR) sees 2026 operating expenses $225M-$255M vs. $343M in 2025
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ESPR:
- Balanced Risk-Reward Keeps Esperion at Hold Amid Complex Corstasis Acquisition and CHF Market Challenges
- Esperion to Acquire Corstasis, Expanding Heart Failure Portfolio
- Esperion signs definitive acquisition of Corstasis Therapeutics
- ESPR Earnings this Week: How Will it Perform?
- Esperion Therapeutics: Strengthened Bempedoic Acid Patent Protection and Growing Cardiovascular Franchise Support Buy Rating